Daiichi Sankyo Co Ltd logo

Daiichi Sankyo Co Ltd

DSKYF · OTC · Pharmaceuticals, Biotech

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin.

Current Price
—
Market Cap
—
Return Since Last Split
-36%
Last Split
Sep 29, 2020
Total Splits
1
Cumulative Multiple
3×

What If You Bought DSKYF Earlier?

Investment
Purchase Date (Before Split)
Worth Today
—
300 shares · 3×

Estimate based on split history only. Excludes dividends, fees, taxes, and intraday movement.

Stock Split History

Newest split first. Cumulative multiple = compounded growth within the displayed company lineage.

Split DatePrice BeforeRatioSplit MultipleCumulative
Sep 29, 2020$30.753-for-13×3×

Daiichi Sankyo Co Ltd Market Cap Timeline

A validated annual market-cap history is unavailable from the current sources. The current market-cap snapshot, when shown above, is not treated as historical evidence. Split markers cover 1 current-security split. Filled dots have market-cap data for that year; hollow dots mark split years outside market-cap source coverage.

Validated annual history unavailable

At least two source-validated annual observations are required before this page draws a market-cap timeline. A current snapshot is not treated as historical trend data.

Recorded split dates

Frequently Asked Questions

Daiichi Sankyo Co Ltd's latest record in the split calendar is a 3-for-1 forward split effective 2020-09-29.
Stay in the loop

Never Miss a Stock Split Again

Get personalized stock split alerts. Choose what you receive and how often.

Your email is securely stored. We’ll only contact you about updates you choose. Unsubscribe anytime.